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A causal link between Human Papillomavirus (HPV) and breast cancer (BC) remains
controversial. In spite of this, the observation that HPV DNA is over-represented in
the Triple Negative (TN) BC has been reported. Here we remark the high prevalence
of HPV DNA (44.4%) in aggressive BC subtypes (TN and HER2+) in a population of
273 Italian women and we convey the presence of HPV DNA in the epithelial and
stromal compartments by in situ hybridization. As previously reported, we also found
that serum derived-extracellular vesicles (EVs) from BC affected patients contain HPV
DNA. Interestingly, in one TNBC patient, the same HPV DNA type was detected in the
serum-derived EVs, cervical and BC tissue samples. Then, we report that HPV DNA can
be transferred by EVs to recipient BC stromal cells that show an activated phenotype
(e.g., CD44, IL6 expression) and an enhanced capability to sustain mammospheres (MS)
formation. These data suggest that HPV DNA vehiculated by EVs is a potential trigger
for BC niche aggressiveness.
Keywords: Human Papillomavirus (HPV), extracellular vesicles (EVs), triple negative BC, stromal cells, circulating
HPV DNA
INTRODUCTION
Human Papillomavirus (HPV) is a common pathogen in oropharyngeal and ano-genital cancers
(1). The oncogenic potential of HPV resides on its capacity to interfere with some important
regulators of the cell cycle via its oncogenic proteins E6 and E7. HPV has also been reported in
a variety of cancers i.e., glioblastoma, colorectal, lung and breast cancers (2–5), but its pathogenic
role remains controversial. Globally, breast cancer (BC) is the most frequent cancer among women
(6). Some authors reported an increased risk of BC incidence among patients with a previous
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cervical dysplasia, suggesting an interplay between cervical
infection and the development of BC (7). In the past decades, a
wealth of studies have analyzed the presence of HPV DNA in BC
tissues with a prevalence rate ranging from 0 to 86%, discrepancy
mainly attributed tomethodological and geographical differences
across studies (8, 9). Recent literature, using the more powerful
next generation sequencing, don’t give support to viral infection
in disease causality of BC (10). On the other side, some authors
observed an association between TNBC phenotype and HPV
positivity (11, 12), leading to the hypothesis that an imbalance
of the native and/or adaptive immunity could favor the infection
in a specific anatomical area, as well as the activation of an
uncontrolled proliferation cycle. An unsolved problem is the
origin of HPV DNA spreading to the mammary gland. Some
authors speculate an ascending pattern of dissemination (13).
However, circulating HPV DNA may contribute to HPV DNA
spreading in unconventional site of infection. At this regard,
some authors reported circulating HPV DNA in the serum of
patients with HPV-associated invasive cancer (10) and as marker
for disease extent and recurrence (14). We also found HPV
DNA in the serum derived-extracellular vesicles (EVs) of breast
pathologies affected women as well as in patient with HPV DNA
positive squamous cell carcinoma of the middle rectum (15, 16).
EVs are a heterogeneous population of vesicles, which includes
exosomes, microvesicles, and apoptotic bodies that differ in size
and biophysical properties (17). EVs are released from different
types of tissue, cells and biological fluids and contain nucleic
acids, proteins, non-coding RNAs and viral nucleic acids (18–
22). Interestingly, exosomes and EVs have been implicated in
HPV transmission and carcinogenesis (23–29). Moreover, some
authors reported how stress condition and DNA damage induced
by radiation therapy, can influence stromal compartment and
the uptake of EVs (30, 31). Here, we report that HPV DNA is
associated with aggressive BC phenotypes and that HPV DNA is
present in serum derived-EVs of TNBC affected patients. Finally,
we showed that EVs transfer HPV DNA to BC stromal cells,
which acquire an inflammatory activated phenotype.
MATERIALS AND METHODS
Formalin Fixed Paraffin-Embedded Breast
Cancer (FFPE BC) Tissues Collection and
Molecular Characterization
BC tissues (n = 273) were collected and archived at Sant’Orsola
Malpighi Hospital, Bologna, Italy, by the Breast Cancer
and Pathology Units, respectively. This study was approved
by the local ethics committee (number 145/2015/U/Sper)
and signed informed consent was obtained from all the
patients enrolled. To define invasive carcinoma bioprofile,
sections were treated in an automated immunostainer
(Benchmark Ultra, Ventana Diagnostic Systems, USA)
and immunostained using anti-ER (clone SP1), anti-PR
(clone 1E2), anti-Ki67 (clone 30-9), anti-Her2 (clone
4B5) pre-diluted monoclonal antibodies all from Ventana.
Sections were retrieved using UltraCC1 Tris-HCl buffer. The
immunological reaction was visualized using the OptiView
DAB Detection system (ER, PR, Ki67) or UltraView DAB
Detection system (Her-2). Sections were counterstained on
board with Hematoxylin II and Bluing reagents (Ventana
Diagnostic Systems, USA). Immunostaining for ER, PR, and
Ki67 was quantified using image cytometry with the IMAGE
ProPlus 5.1 software (Media Cybernetics Inc., USA) and
expressed as percentage of immunostained neoplastic cells.
Her2 expression was evaluated following ASCO/CAP 2013
and 2018 recommendations and classified according to the
Score 0/1+/2+/3+ method. Luminal cases were classified as
Luminal A or Luminal B following the St. Gallen 2013-15
consensus recommendations, in particular we considered 20% as
cut-off value.
HPV DNA Chromogenic in situ
Hybridization (CISH)
CISH was performed by the ZytoFast R©Plus CISH
Implementation Kit HRP-DAB (ZytoVision, Bio-Optica,
Milan, Italy) using the ZytoFast HPV type 16/18 Probe
digoxigenin-labeled probes according to manufacturer’s
protocol in order to detect HPV 16 and 18 in formalin fixed
paraffin embedded BC and stromal compartment. HeLa and
CaSki pellets were formalin fixed and paraffin embedded
and were used as positive controls. As negative control we
used HPV DNA negative cell lines (MCF7). Briefly, 20 × 106
cells were centrifuged at 3,000 g for 10min and resuspended
in a small volume of PBS and mixed with agar. Then cells
were fixed in formalin. We also used the ZytoFast DNA
(-) Control Probe for assessing the unspecific background
staining in formalin-fixed, paraffin embedded tissue or cells
by chromogenic in situ hybridization (ZytoVision, Bio-Optica,
Milan, Italy).
Isolation of Breast Cancer
Derived-Fibroblasts (BC DFs)
BC DFs (n = 20), were obtained from Breast Cancer Unit,
Sant’ Orsola Malpighi Hospital, with approval of the internal
local ethics committee (006/2012/U/Tess; 145/2015/U/Sper) and
upon the patient’s written informed consent. Tissues samples
were minced with scalpels in a tissue culture dish and then
enzymatically dissociated in 5mL of mammary epithelial growth
medium (Cambrex, Milan, Italy) supplemented with 2% bovine
serum albumin (Fraction V, Fisher Scientific), 10 ng/mL cholera
toxin, 300 units/mL collagenase (Invitrogen, Milan, Italy), and
100 units/mL hyaluronidase (Calbiochem, Milan, Italy) at 37◦C
for 18 h. On the second day, the suspension was centrifuged
at 80 × g for 4min to separate the epithelial and fibroblast
cells. Fibroblast cells were pelleted by centrifugation at 100
× g for 10min followed by two washes with DMEM/F12
medium. The cell pellet was resuspended in DMEM/F12medium
supplemented with 5% FBS (Invitrogen, Milan, Italy) and
5µg/mL insulin and plated in 25 cm2 tissue culture flasks. The
cultures were incubated for 2–3 days at 37◦C at 5% CO2. All the
samples were stored at−80◦C until use.
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TABLE 1 | Primers used for mRNA and DNA analysis by PCR assays.
Target Sequence (5′−3′) NT position Length
(bps)
Assay
L1 HPV DNA
(MY09/11)
CGTCCMARRGGAWACTGATCa N.A. N.A. PCR
GCMCAGGGWCATAAYAATGGa N.A.
E6 HPV16 DNA CAACAGTTACTGCGACGTGAG 206b 349 PCR
GCTGGGTTTCTCTACGTGTTC 554b
E7 HPV16 DNA CAACTGATCTCTACTGTTATGAGCAAc 617b 73 Real-time and Digital PCR
CCAGCTGGACCATCTATTTCAc 689b
E1 HPV16 DNA Taqman probe (Vi03453396_s1, Life Technologies) N.A. 153 Real-time and Digital PCR
IL6 RNA Taqman probe (Hs00985639_m1, Life Technologies) N.A. 70 Real-time PCR
CD44 RNA Taqman probe (Hs01075861_m1, Life technologies) N.A. 66 Real-time PCR
Cyclin-D1 RNA ACAAACAGATCATCCGCAAACAC 730d 144 Real-time PCR
TGTTGGGGCTCCTCAGGTTC 873d
c-Myc RNA CTCTGACCTTTTGCCAGGAG 2036e 248 Real-time PCR
CCTACCCTCTCAACGACAGC 1789e
ACTB DNA CCACACTGTGCCCATCTACG 1358f 98 Real-time PCR
AGGATCTTCATGAGGTAGTCAGTCA 1456f
ACTB DNA Taqman probe (Hs03023880_g1, Life Technologies) N.A. 139 Real-time PCR
GUSB RNA Taqman probe (Hs99999908_m1, Life Technologies) N.A. 81 Real-time PCR
N.A. not available.
aDegenerate nucleotides of primers: W = T, C; Y = C, T; R = A,G; M = A,C.
bNCBI Reference Sequence HPV16: NC_001526.4.
cLNA Probe #63 (seq. AGGAGGAG),UPL Roche.
dNCBI Reference Sequence Cyc-d1: NM_053056.2.
eNCBI Reference Sequence C-Myc: NM_001354870.1.
fNCBI Reference Sequence ACTB: NC_000007.14.
Isolation of EVs From Serum Samples of
BC Affected Patients
Serum specimens (n = 59), cervical cytological scrapes (n = 6)
and TNBC tissues (n= 6), were collected from the Breast Cancer
Unit, Sant’Orsola Malpighi Hospital, Bologna (Italy), from BC
affected patients. This study was approved by the local ethics
committee (145/2015/U/Sper) and patient’s written informed
consent was obtained. EVs were isolated from patients’s serum
specimens as reported by King et al. (32). Briefly, the serum
specimens were centrifuged at 500 g for 10min, at 18,000 g for
30min and at 100,000 g for 120min twice, to obtain the EVs
pellet. The pellet was resuspended in 50 µL of PBS and was
DNAseI digested (DNase I RNase-free 1 U/µL, Thermo Fisher,
Milan, Italy) before nucleic acid extraction. EVs were counted by
using theNS500 nanoparticle characterization system (Nanosight
Malvern Instruments).
HPV DNA Detection
DNA extraction from three 10µm thick formalin fixed paraffin-
embedded (FFPE) BC tissues was performed using NucleoSpin
DNA FFPE Tissue kit (Macherey-Nagel, Milan, Italy). DNA
extraction from BC DFs, CaSki derived-EVs, serum derived-EVs
and from 6 TNBC affected patients specimens were performed
by NucleoSpin Tissue kit (Macherey-Nagel, Milan, Italy). DNA
concentration was measured by Thermo Scientific NanoDropTM
1000 Spectrophotometer and stored at −20◦C until use. HPV
DNA detection in 273 BC tissues and 59 serum derived-EVs, was
performed by Mass spectrometry assay (Mass Array Platform,
Agena Bioscience, Hamburg, Germany), as previously described
(15, 33). Briefly, this method is able to simultaneously detect
and type 16 HPV DNA types (HPV16, 18, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 68, and 73) in a single well.
The viral DNA is amplified by a multiplex PCR with type-
specific primers and the amplified product is extended at its 3′
terminal base with type specific primers. This method was as
sensitive to detect up to 100 copies/reaction of HPV 16 and 18.
HPV DNA detection in BC DFs and in the 6 TNBC affected
patients specimens was performed by conventional PCR with
MY09/11 and E6 HPV16 primer set on T100 Thermal cycler
Bio-Rad (Table 1). Each amplification reaction was performed
by GoTaq R©Flexi DNA Polymerase kit (Promega, Milan, Italy)
following the manufacturer’s instruction. Amplified products
were detected on 1.8% agarose gel by using ChemiDocTM
XRS+ System (Bio-Rad). Then, sequencing (GATCBiotech DNA
Sequencing) of purified products was performed and nucleotide
sequences were edited using the programme BioEdit Sequence
Alignement. The sequences were compared with those deposited
in the GenBank Database.
Next Generation Sequencing (NGS)
NGS approach was used to analyze total DNA from
serum derived-EVs of the patient with cervix, blood
and BC coinfection of the same HPV type, namely
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FIGURE 1 | Association between HPV DNA and Breast Cancer (BC). (A) HPV DNA prevalence in 273 FFPE breast cancer (BC) tissues. (B) Percentage of HPV
genotypes in the 83 FFPE HPV positive BC tissues. (C) Association of HPV DNA in the different BC subtypes (Lum A and B, HER2+ and TN), p-value = 0.0181. (D)
Association between HPV DNA and extent of lymph nodes invasion in LumA BC (n = 136, missing 6 cases), p-value = 0.0007. (E) Association of Ki67 in HPV DNA
positive LumB BC (n = 73), p-value = 0.0188. (F) HPV DNA Chromogenic in situ Hybridization assay (CISH), in BC tissues. HPV DNA negative BC tissues, HeLa and
CaSki cell lines are reported as controls. (G) HPV DNA CISH assay in stromal compartment of BC tissues. (H) PCR analysis of E6 HPV16 DNA in 9 BC tissues and 9
corresponding isolated BC DFs (S1-S9 samples). (I) Real Time PCR analysis of HPV16 E7 DNA in HPV16 positive ex vivo isolated S1 BC DF cultured for at least 12
passages. This sample are used as reference to detect HPV16 DNA. Data are presented as mean ± s.d.; p refers to t-test; *p < 0.0001.
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HPV53. We amplify total DNA by modified degenerate
FAP59/64 primers: 5′- CGTATCGCCTCCCTCGCGCCA-
TCAGACGAGTGCGTTAACWGTIGGICAYCCWTATT-3′ and
5′- CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGTCC
WATATCWVHCATITCICCATC-3′ (W = T, C; I = inosine;
Y = C, T; B = G, C, T; H = A, C, T; V = A, C, G) (34), which
are able to amplify a broad spectrum of mucosal and cutaneous
Papilloma Viruses (PVs). PCR was carried out on T100 Thermal
cycler (Bio-Rad, Milan, Italy) using the following parameters:
10min at 94◦C and then 45 cycles of 30 s at 94◦C, 30 s at 50◦C
and 60 s at 72◦C. Then sequencing reaction was performed on
Roche 454 Instrument following the manufacturer’s instruction.
PRINSEQ was used to filter, reformat, and trim sequence data
(http://prinseq.sourceforge.net/) (35), the bases that fell below
the PHRED score of 20 have been removed, reads with a length
≥20 bp were selected. Then raw files were analyzed using QIIME
(v. 1.4.0-dev) (36) that was used to assign the taxonomy of
each sequence (code “assign_taxonomy.py”), considering all
the complete HPV genomes from Papilloma Virus Episteme
web-based tool (humans and non-humans) (37).
Isolation of Extracellular Vesicles (EVs)
From Culture Media of CaSki Cells
HPV DNA positive cancer cell lines (CaSki) were purchased
from the American Type Culture Collection (ATCC). CaSki
cells were established from a metastasis of a cervical cancer and
are reported to contain about 600 copies per cell of integrated
HPV16 DNA. CaSki cell lines were cultured in RPMI-1640,
supplemented with 10% fetal bovine serum (Euroclone, Milan,
Italy), 1% glutamine and 1% penicillin/streptomycin at 37◦C in
5% CO2 humidified atmosphere. EVs were isolated from 80ml
of HPV DNA positive CaSki cell lines supernatant, maintained
in serum-free medium for 48 h at 37◦C in 5% CO2 humidified
chamber as reported previously.
HPV DNA Quantification
HPV DNA quantification in CasKi derived-EVs was performed
by Taqman assay (TaqMan Universal PCR Master Mix, Thermo
Fisher Scientific, Milan, Italy) and SYBR Green (SYBR R© Select
Master Mix for CFX, Life Technologies, Milan, Italy) following
the manufacturer’s instruction, with E1, E7, and E6 HPV16
primer pairs (Table 1). The beta-Actin was used as endogenous
controls. The data were analyzed by using the 2−11CT method.
Each sample was analyzed in triplicate. Digital PCR was
performed on QuantStudio R© 3D Digital PCR System (Life
Technologies, Milan, Italy), with E7 and E1 HPV16 primer pairs
(Table 1) by Taqman assay (Life Technologies, Milan, Italy),
following the manufacturer’s instruction.
Nanosight and FACS Analysis of EVs
EVs were diluted in 1ml of PBS EVs-free, loaded into the sample
chamber of an LM10 unit (Nanosight, Malvern, UK) and three
videos of either 30 or 60 s were recorded of each sample. This
analysis allows to identify the vesicles size’s distribution profile
and their concentration (particles/ml). EVs surface antigens
were investigated with the MACSPlex Exosome kit (cat. no.130-
108-813, Miltenyi Biotec GmbH, Gladbach, Germany) (38).
MACSPlex Exosome kit detects 37 surface markers, including:
CD9, CD81, CD63, cell adhesion, migration, proliferation and
immune cells markers. Briefly, after isolation, EVs were diluted
in MACSPlex buffer and stained according to manufacturer’s
instructions and samples were analyzed by FACSCanto flow
cytometer (BecktonDickinson). At least 10,000 events per sample
were recorded and data were analyzed with FACSDiva software.
The median fluorescence values plotted in the graph were
background corrected and normalized on CD63/81/9 median
signal intensity. Negative values were excluded from the plot.
EVs Administration to BC DFs
100,000 BC DFs were seeded in DMEM medium supplemented
with 20% FBS, 1% glutamine and 1% penicillin/streptomycin in
a 6 well plate and incubated at 37◦C in 5% CO2 humidified
atmosphere. After 24 h, BC DFs were grown in DMEM serum-
free and then were exposed to a single radiation dose of 7.5Gy
using a photon beam generated by a roentgen with 180 kV and
filtration 0.35 Cu−1.5 Al. For the setup we used a base of 8 cm of
solid water and a field 20 × 20 cm2 with dose rate of 62 CGy/m.
An amount of 2 × 1010 CaSki-derived EVs in 1ml volume of
medium was administered at time 0 to irradiated 100,000 BC
DFs, the medium was removed at 24 h post irradiation and
substituted at 24, 48, and 72 h with fresh DMEM without HPV
DNA positive EVs. At day 4, the medium was collected and
1ml volume was administered to 20,000 MCF7 cells cultured in
3D model in low attachments plates to perform MCF7 derived-
MS assay.
RNA Extraction and Gene Expression
Analysis
RNA extraction was performed on EVs-administered BC DFs
by TRIzol reagent (Life Technologies, Milan, Italy). An amount
of 0.1–1 µg of total RNA was retro-transcribed by the Master
RT plus PCR system kit (LifeTechnologies, Milan, Italy). RNA
concentration was measured by Thermo Scientific NanoDropTM
1000 Spectrophotometer and stored at −80◦C until use. cDNA
was amplified by SYBR Green (SYBR R© Select Master Mix
for CFX, Life Technologies, Milan, Italy) and Taqman assay
(TaqMan Universal PCR Master Mix, Thermo Fisher Scientific,
Milan, Italy), following the manufacturer’s instruction, with
IL6, CD44, c-Myc, and Cyclin-D1 primers (Table 1). Real
time PCR was performed on Mx3000P Stratagene instrument
(Agilent Technologies). The beta-glucuronidase gene, were used
as endogenous controls. The data were analyzed by using the
2−11CT method. Each sample was analyzed in triplicate.
MCF7 and MDA-MB-231 Derived-MS Assay
The MCF7 and MDA-MB-231 human BC cell lines were
purchased by the American Type Culture Collection (ATCC).
MCF7 and MDA-MB-231 cells were cultured in RPMI-
1640 and DMEM respectively, supplemented with 10% fetal
bovine serum (Euroclone, Milan, Italy), 1% glutamine and
1% penicillin/streptomycin at 37◦C in 5% CO2 humidified
atmosphere. An amount of 20,000 BC cells were resuspended
in medium serum-free and filtered through a 40µm nylon
mesh (Becton Dickinson, Franklin Lakes, NJ) before being
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suspended in 1.5 cm2 low attachment wells (Becton Dickinson,
Franklin Lakes, NJ) with 1ml of medium serum-free, 1%
penicillin/streptomycin. BC cells were incubated at 37◦C in 5%
CO2 humidified atmosphere. MCF7 and MDA-MB-231 derived-
MS were counted after 6 days of incubation as average number of
cells per field of view with OLYMPUS CKX41 microscopy.
Soft Agar Assay
The Soft Agar Assay is an anchorage independent growth assay
in soft agar, which is considered the most stringent assay for
detecting malignant transformation of cells. In brief, 5,000 cells
were cultured on a 24 well plate containing 1% base agar and
0.35% top agar in the DMEM medium and incubated at 37◦C
for 15 days. Plates were stained with 0.005% crystal violet +
methanol for 1 h. Colonies were acquired with ChemiDocTM
XRS+ System (Bio-Rad) and counted using ImageJ software.
Clonogenic Assay
Clonogenic Assay or Colony Formation Assay is an in vitro cell
survival assay based on the ability of a single cell to grow into
a colony. This assay measure cells survival skills based on the
number of colonies formed after low density seeding. In brief,
5000 cells were cultured on a 24 well plate at 37◦C for 15 days.
After 15 days medium was removed and cells were rinsed with
PBS. Fixation and staining of clones were done with a mixture
of 0.5% crystal violet in 50/50 methanol/water for 30min. Plates
were rinsed with water and left for drying at room temperature.
Counting of clones was done on the following day. Clones
were acquired with ChemiDocTM XRS+ System (Bio-Rad) and
counted with ImageJ software.
Statistical Analysis
Statistical analysis was performed by SPSS software (SPSS
Incorporation). Chi square test was calculated with Monte Carlo
method. The exact p-value was calculated by un-paired t-test
(two groups comparisons) and one-way ANOVA (>2 groups
comparisons). Post-hoc t-test values were corrected for multiple
comparisons according to Bonferroni correction. The statistical
analysis was performed with Graph-pad Prism 6 software.
TABLE 2 | Clinical pathological variables of 273 BC samples.
Subtype/Stage/Molecular marker HPV DNA+ HPV DNA-
T1 (n = 181*) 53 128
T2 (n = 70) 23 47
T3 (n = 9) 2 7
T4 (n = 13) 5 8
N0 (n = 150◦) 36 114
N1 (n = 59◦) 20 39
N2 (n = 24◦) 9 15
N3 (n = 29◦) 16 13
G1 (n = 41ª) 8 33
G2 (n = 134ª) 40 94
G3 (n = 77ª) 28 49
*missing 3 cases; ◦missing 11 cases; ª missing 21 cases; BC, Breast Cancer; T1-4, Size
of the tumor; N0-3, Lymph node status; G, Grading.
RESULTS
Association Between HPV DNA With TNBC
and BC Malignant Features
This study started by investigating the presence of sixteen
high-risk mucosal HPV DNA types by MALDI-TOF technique
(33) to prove the association of HPV with the TNBC subtype.
Purposely, we retrospectively assessed HPV DNA in 273 FFPE
BC tissues and we found that 83 samples (30.4%) were HPV
DNA positive (Figure 1A) and that HPV16 was the most
prevalent HPV type (Figure 1B). We found that HPV DNA was
over-represented in the TN subtype (12/27, 44.4%), in aggressive
HER2+ BC (15/31, 48.4 %) compared to Luminal A (LumA)
(34/142, 23.9%) and Luminal B (LumB) ones (22/73, 30.1%)
(Monte Carlo X square test: P = 0.0181, Figure 1C). These data
support the previously association between TN subtype and
HPV DNA (12). Notably, in LumA cases HPV DNA presence
was proportionally related to the extent of lymph node invasion
(pN1 = 31%; pN2 = 30%; pN3 = 70%—Monte Carlo X2 square
test: P = 0.0007, Figure 1D, Table 2, Supplementary Table 1).
HPV DNA was also associated with the highest proliferation
rate (Ki67), only in the LumB subtype (p = 0.0188) (Figure 1E,
Supplementary Table 2). We also assessed the presence of HPV
DNA in BC specimens by Colorimetric in situ Hybridization
(CISH) (Figure 1F). We observed the presence of HPV DNA
in BC epithelial cells, in the stromal compartment and in
endothelial cells (Figure 1G). To confirm the presence of HPV
DNA specific signal in stromal compartment, we assessed HPV
DNA by PCR in ex vivo cultured BC derived-fibroblast (DFs).
We found the presence of HPV16 DNA in 2 out of 9 BC DFs, one
from an HPV16 DNA positive TNBC and one from an HPV16
DNA positive LumB cancer (Figure 1H). BC DF from the
HPV16 DNA positive TNBC, still showed the presence of HPV
DNA, after 12 in vitro passages (Figure 1I). These data support
the presence of HPV DNA in the breast tissue and encouraged us
to investigate how HPV may spread to the mammary gland and
how the presence/persistence of HPV DNA in fibroblasts may
influence the tumorigenic process.
HPV DNA in Circulating EVs of TNBC
Patients
We previously demonstrated that circulating HPV DNA can be
found in serum derived-extracellular vesicles (EVs) in women
TABLE 3 | HPV DNA assessment in 59 serum derived-EVs.
BC subtype N HPV DNA positive
specimens (%)
HPV DNA negative
specimens (%)
HPV
genotypes
LumA 23 3 (13.0%) 20 (87%) 16, 16/31,
16/33
LumB 22 0 (0.0%) 22 (100.0%) -
HER2+ 8 2 (25.0%) 6 (75.0%) 31,18
TN 6 2 (33.3%) 4 (66.7%) 53, 6
59 7 (11.9%) 52 (88.1%) -
BC, Breast Cancer; LumA, Luminal A; LumB, Luminal B; HER2+, Human Epidermal
growth factor Receptor 2; TN, Triple Negative.
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TABLE 4 | HPV DNA assessment in cervical scrapes, serum derived-EVs and BC
tissues from 6 TNBC affected patients.
Patient HPV DNA in cervical
scrape
HPV DNA in
serum-derived EVs
HPV DNA in
TNBC tissue
N1 Neg Neg Neg
N2 Neg Neg HPV16
N3 Neg Neg Neg
N4 Neg (HPV16 past infection
and CIN1 lesion)
Neg HPV16
N5 HPV53 HPV53 HPV53
N6 HPV6 HPV6 Neg
EVs, extracellular vesicles; TNBC, triple negative breast cancer; CIN1, cervical
intraepithelial lesion grade 1.
with breast pathologies as well as in patient with HPV DNA
positive squamous cell carcinoma of the middle rectum (15, 16).
Here, as described in the first part of the study approved by
the local ethics committee (145/2015/U/Sper), we enrolled 59
BC affected-patients and we searched for the presence of HPV
DNA in the serum derived-EVs. We found the presence of HPV
DNA in 7 patients (11.9%): 3 out of 23 LumA (13.0%), 2 out
of 8 HER2+ (25%) and 2 out of 6 TNBC (33.3%) (Table 3). As
delineated in the second phase of the study, of all the TNBC
patients, whose EVs were available, we collected cervical scrapes
and FFPE BC tissues, with the aim to investigate HPV DNA
dissemination by EVs from a primary site of infection to distant
sites, e.g., breast tissues. Three out of 6 TNBC tissues (50%)
were positive for HPV DNA (Table 4). In particular, in one
patient HPV16 DNA was detected both in cervical scrape and
BC tissue sample. In another one, we found HPV6 DNA, in
cervical specimen and serum derived-EVs (Table 4). In the last
patient, we detected the same HPV DNA strain (HPV53) in
cervical scrape, in serum-derived EVs and in the BC tissue
(Figures 2A–E). We also confirmed the presence of high levels of
HPV53 (12732 reads, 99.72%) in the serum-derived EVs, by NGS,
with a primer set able to amplify both mucosal and cutaneous
HPV types. Even if the distribution of HPV 53 is more common
in CIN1 (cervical intraepithelial neoplasia grade 1) and normal
cases, this genotype is considered an high risk HPV (39). These
data support our hypothesis that HPV DNA can be vehiculated
by EVs from primary sites of infection, e.g., cervical tissues,
to distant body districts, such as the mammary gland, where
HPV DNA can be found even if cells are not permissive for
viral replication.
HPV DNA Transfer to Fibroblasts Is
Mediated by EVs
We then tested the hypothesis that EVs can transfer HPV DNA
to negative recipient cells. Purposely, we isolated EVs from the
supernatant of CaSki cell line, which contain integrated HPV16
DNA and not complete viral particles. EVs were characterized by
Nanosight, and FACS analysis (Supplementary Figures 1A,B).
Before DNA extraction, EVs were treated by DNAseI to avoid cell
free DNA contamination and were assessed by HPV16 specific
Digital PCR assay (Figure 3A). Then, we tested the capability of
CaSki-derived HPVDNA+ EVs to transfer HPVDNA to ex vivo
isolated BC DFs. At this purpose we administered an arbitrary
fixed amount of 2∗1010 EVs to HPV negative BC DFs and we
observed different capability to uptake and to retain HPV DNA
from EVs after 4 days of exposure (Figure 3B). Interestingly, it
has been reported that EVs uptake were increased when recipient
cells are exposed to radiation (30). Purposely, we first exposed
9 HPV negative BC DFs to a single dose of 7.5 X-Ray radiation
and then we administered them 2∗1010 CaSki derived-HPV
DNA+EVs. As previously reported, we found heterogeneous
capability to retain HPV DNA along with BC DFs strains. In
particular, after X-Ray single dose exposure, all but one BC
DFs strains show detectable level of HPV DNA compared to
4 out of 9 BC DFs without X-Ray exposure (Figure 3C). We
also analyzed the effects of HPV DNA+ EVs uptake in BC
DFs by analyzing some proliferation and stromal markers. We
found an increased level of c-Myc and Cyclin-D1 expression
in exposed DFs, compared to not exposed cells, as well as an
increased level of stromal activation markers, e.g., IL6 and CD44
(Figure 3D). Accordingly, the supernatant of BC DFs exposed
to HPV DNA+ EVs was more capable to elicit MDA-MB-
231 and MCF7 derived-MS formation than control (Figure 3E,
Supplementary Figure 1C). Accordingly to the finding that HPV
DNA is more represented in TNBC, we administered HPV
DNA+ EVs on MDA-MB-231. We observed an enhanced
cellular invasion and proliferation by Soft-Agar and Clonogenic
Assays (Figures 4A,B). HPV DNA+ EVs contribution in the
cellular proliferation and aggressiveness were also confirmed in
BC DFs exposed to CaSki derived-EVs (Figures 4C,D). These
results showed that HPV positive EVs increased pro-tumorigenic
activity in the BC niche.
DISCUSSION
Breast cancer is a frequent pathology in the female population,
representing 24% of diagnosed pathologies and 15% of mortality
(40). Despite HPV DNA has been largely investigated in breast
cancer tissues, its role in breast pathology remains to be
elucidated (8, 9). The data presented here report that HPV DNA
is over-represented in the TNBC and HER2+ BC tissues than in
the Luminal ones. Furthermore, among Luminal subtypes, HPV
DNA was more prevalent in highly lymph-node-invasive LumA
cancers tissues as well as among LumB tissues showing high
levels of Ki67 expression. As a support of this conclusion is the
finding that, according to recent literature, HPV DNA is more
represented among TNBC tissues (11, 12). Overall, these data
sustain the notion that HPV DNA is present in breast cancers
with enhanced aggressive features. Nevertheless, we presume that
HPV DNA is not per se sufficient to induce the carcinogenic
process but, as environmental factor, it may contribute to
delineate the BC tumorigenic phenotype. Interestingly, we
observed the presence of HPV DNA not only in the epithelial
compartment but also in the stromal one by in situ hybridization.
We support this finding by analyzing ex vivo-cultured fibroblasts,
derived from BC tissues, which showed the presence of HPV
DNA, even after several in vitro culture passages. Notably, the
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FIGURE 2 | HPV DNA assessment in cervical scrape, serum derived-EV and BC tissues of TNBC affected patients. (A) PCR analysis of cervical scrape, serum
derived-EVs and BC specimens with MY09/11 consensus primer: B-blank, 1-serum derived-EVs, 2-servical cytological specimen, 3-BC tissue. (B–E) Sequencing of
PCR product obtained from serum-derived EVs (B), cervical scrape (C), and BC tissue (D). GenBank database are used as reference sequence of HPV53 genotype
(NC_001593.1) (E).
presence of HPV DNA in human primary fibroblasts, that lack
receptors for HPV, has been reported as mediated by apoptotic
bodies derived from HPV DNA positive cell lines (23, 26, 28). In
this regard, we previously demonstrated that HPV DNA may be
vehiculated by circulating EVs in patients with breast pathologies
and squamous cell carcinoma of the middle rectum (15, 16). We
thus hypothesized that HPV DNA transfer to recipient cells may
be supported by EVs. Here, we found the presence of HPV DNA
in 7 out of 59 serum derived-EVs of BC affected patients. Two
out of 7 were EVs from TNBC patients. Interestingly, in one of
the two cases, the same HPV genotype, i.e., HPV53, was shared
among the EVs, the breast tissue and the cervical specimen. HPV
53 is considered a high risk HPV, even if its distribution is more
common in CIN1 (cervical intraepithelial neoplasia grade 1) and
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FIGURE 3 | HPV DNA transfer to the BC niche is mediated by EVs. (A) Digital PCR analysis of HPV DNA content (E1 and E7) in CaSki cells and CaSki derived-EVs
(copies/ul). (B) Real Time PCR analysis of HPV16 DNA content (E7) in BC DFs exposed to CaSki derived-EVs for 4 days (S10-S11 samples). The specimens were
analyzed in quadruplicate (R1-R4). The data were normalized on HPV DNA content of the ex vivo isolated S1 BC DF sample. (C) Real Time PCR analysis of HPV DNA
(E7) in 9 BC DFs exposed to a single dose of 7.5Gy of X-Rays and to CaSki derived-EVs for 4 days (S12-S20 samples) (n.d., not detected). (D) Real Time PCR
analysis of c-Myc, Cyclin-D1, IL6 and CD44 mRNAs in BC DFs of exposed to CaSki derived-EVs upon 4 days (S10-S11 samples). (E) MS assay of MDA-MB-231
cells administered with the supernatant of BC DFs for 6 days, compared to control. MS were counted and represented as mean ± s.d. p refers to t-test; *p < 0.0001.
normal cervix vs. high-grade cervical lesions and cancer. In any
case, the presence of anHPVDNA+ high-grade cervical lesion or
cancer does not seem a prerequisite for HPV DNA shedding via
EVs, in fact none of our 6 TNBC affected patients showed high
grade cervical lesions. Furthermore, in 2 out of 3 HPV DNA +
TNBC we did not observed the simultaneous presence of HPV
in the BC tissue, cervix and EVs (see Table 4). In one case, the
cervical infection has already been resolved and in the other one,
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FIGURE 4 | Effects of HPV DNA+ EVs transfer on epithelial and stromal compartments. (A,B) Soft-agar and Clonogenic Assays on MDA-MB-231 after 15 days of
exposure to CaSki-derived EVs, versus control (three independent experiments). Data are presented as mean ± s.d. (C,D) Soft-agar and Clonogenic Assays on BC
DFs after 15 days of exposure to CaSki-derived EVs, versus control (three independent experiments). Data are presented as mean ± s.d.; p refers to t-test;
*p < 0.0001.
we cannot exclude that an alternative primary site of infection has
been involved in this dynamic process, e.g., the oropharyngeal
site or the rectum. Eventually, it seems that our findings depicted
a static picture of a long-lasting dynamic process that might
involve the shedding of HPV DNA + EVs from a primary site
of infection to distant districts, e.g., the breast tissue. This finding
is reminiscent of the previous reported by Lawson et al. (7). On
the basis of these observations, we tested in vitro the hypothesis
that HPV DNA positive EVs are able to transfer their cargo to
recipient cells. At this regard, we administered HPV DNA +
EVs to BC DFs and we found heterogeneous but reproducible
persistence of HPV DNA in recipient cells. Moreover, we found
that the exposure of BC DFs to stress (single dose of 7.5Gy of X-
Rays) increased the capability to retain HPV DNA after exposure
to HPV DNA + EVs. Hence, our data indicate that HPV DNA
can be transferred to BC DFs by EVs and that this phenomenon
is enhanced by cellular stress. It is worth noting that radiation
exposure increase the uptake of EVs and the internalization
of EVs carried genetic material (30, 31). In agreement with
literature (24, 25, 29), we showed that the effect of HPV DNA
+ EVs transfer was to induce an activated phenotype in BC
DFs, as demonstrated by the increased expression of fibroblast
activation and proliferation markers. At this regard, we show
that HPV DNA transfer to stromal cells may indirectly influence
the aggressiveness of triple negative mammary epithelial cells
by enhancing mammospheres formation, which represents an
index of aggressiveness. Nevertheless, we can’t exclude that
HPV DNA + EVs might transfer other factors, simultaneously
with HPV DNA, able to influence fibroblasts activation and
mammospheres formation. Uptake of nucleic acids via EVs is
a mechanism involved in different types of cancer (29, 41–45).
In particular, it has been observed that the release of some
microRNAs via EVs derived-fibroblast in breast cancer cells,
was able to increase proliferation, EMT and the ability to form
MS (43, 46, 47). Our data suggest that exposure to HPV DNA
positive EVs or apoptotic bodies, see ref. (23, 26, 28), may be
able to remodel the BC microenvironment by activating BC DFs
(30, 44–46).
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In our model, HPV DNA + EVs, produced from a primary
site of infection, are able to transfer their content to recipient
cells that lack HPV receptors, e.g., fibroblasts and BC epithelial
cells. This transfer is not sufficient per se to promote BC butmight
contribute, as environmental factor, to confer aggressive feature
to the BC. The uptake of HPV DNA + EVs in BC stromal cells
may be modulated by inflammatory stimuli, such as exposure to
X-Rays radiation, which may also increase the retention of HPV
DNA in stromal cells. This persistencemay promote an activation
of the stromal compartment, which in turn promote an enhanced
aggressiveness in the BC epithelial counterpart.
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